大量日版口服司美格鲁肽违规“拆盒销售”，相关产品已全部下架

Core Viewpoint - The oral version of semaglutide, a GLP-1 drug by Novo Nordisk, is expected to receive FDA approval for weight loss in the U.S. by the end of this year, while currently, no oral GLP-1 drugs for weight loss are available globally, including Japan [1][6] Pricing and Market Availability - The price of oral semaglutide in Japan is among the lowest globally, with the 3 mg dosage priced at approximately 139.6 Japanese yen per piece, equivalent to about 6.8 RMB [9] - On a major e-commerce platform, the 7 mg dosage of oral semaglutide is priced at 638 RMB for 20 pieces, while the 3 mg dosage is priced at 1498 RMB for 100 pieces [1] Regulatory Compliance - Following inquiries about the legality of sales on e-commerce platforms, all related products were taken down, as semaglutide is a prescription drug that requires a prescription for purchase [6] - Currently, the approved indication for oral semaglutide globally is for the treatment of type 2 diabetes, with no approval for weight loss indications [6][9] Consumer Behavior - Many domestic patients seeking weight loss are reportedly purchasing oral semaglutide through proxy channels from Japan [9] - The oral version of semaglutide, branded as "Nuohexin," is expected to be approved for type 2 diabetes treatment in China in January 2024, and it will also require a prescription for purchase [9]